Navacaprant

Navacaprant

Clinical data
Other names	BTRX-140; CYM-53093; NMRA-140; NMRA-335140
Identifiers
IUPAC name 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
CAS Number	2244614-14-8
PubChem CID	137434175
ChemSpider	78316413
UNII	XK5ILZ28KI
KEGG	D12869
Chemical and physical data
Formula	C25H32FN5O2
Molar mass	453.562 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
InChI InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3 Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N

Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder and bipolar depression.^[1][2][3] It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics.^[2] As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder.^[2][4] In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial.^[5] Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.^[5]

See also

• κ-Opioid receptor § Antagonists
• List of investigational antidepressants

References

1. "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.
2. "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
3. Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.
4. Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.
5. Taylor, Nick Paul (2 January 2025). "Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%". Fierce Biotech. Retrieved 7 March 2025.

External links

• BTRX 335140 - AdisInsight